Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir

Introduction Lenacapavir is the first HIV-1 capsid inhibitor administered subcutaneously twice yearly. While lenacapavir is currently only indicated as salvage therapy, it has the potential to become a foundation of future treatments and to revolutionize HIV prevention.